Viral Vectors and Plasmid DNA Manufacturing Market Report 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Noble Horvath

The MarketWatch News Department was not involved in the creation of this content. Sep 29, 2020 (Profound via COMTEX) — The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases. Based on classification, the proportion of Viral Vectors Manufacturing in […]

The MarketWatch News Department was not involved in the creation of this content.

Sep 29, 2020 (Profound via COMTEX) —
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.

Based on classification, the proportion of Viral Vectors Manufacturing in 2016 is about 79.74%, with revenue about 200 M USD. Based on application, Cancers segment accounted for larger market share in terms of sales in 2016, vascular segmented accounted for more than 61% of the market share in 2016.

North America is the largest consumption place, with a consumption market share nearly 51% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 34% in 2016.

Market competition is intense among top 5. BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

In 2019, the global Viral Vectors and Plasmid DNA Manufacturing market size was US$ 435.7 million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% between 2020 and 2026.

Full Report is Ready, Complete Payment and Get this Premium Research [email protected] https://www.visionresearchreports.com/report/cart/24878

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Viral Vectors and Plasmid DNA Manufacturing market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyzes the impact of Coronavirus COVID-19 on the Viral Vectors and Plasmid DNA Manufacturing industry.

The research report studies the Viral Vectors and Plasmid DNA Manufacturing market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.

Drivers and Restraints

This section covers the various factors driving the global Viral Vectors and Plasmid DNA Manufacturing market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market.

Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market.

Segment Analysis

The global Viral Vectors and Plasmid DNA Manufacturing market is split into two segments, type, and application. The product type briefs on the various types of products available in the market. The report also provides data for each product type by revenue for the forecast time period. It covers the price of each type of product. The other segment on the report, application, explains the various uses of the product and end-users. In the report, the researchers have also provided revenue according to the consumption of the product.

Get Sample Pages of [email protected] https://www.visionresearchreports.com/report/sample/24878

Market Segmentation

Global Viral Vector amp; Plasmid DNA Manufacturing Market, by Type

  • Lentivirus

  • Adenovirus

  • Plasmid DNA

  • Adeno-Associated Virus

Global Viral Vector amp; Plasmid DNA Manufacturing Market, by Application

Global Viral Vector amp; Plasmid DNA Manufacturing Market, by Disease

  • Infectious Disease

  • Genetic Disorders

  • Cancer

Global Viral Vector amp; Plasmid DNA Manufacturing Market, by End Use

  • Research Institutes

  • Biotech Companies

Global Viral Vector amp; Plasmid DNA Manufacturing Market, by Geography

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East and Africa (MEA)

Regional Analysis

The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central amp; South America, Middle East amp; Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.

Key Players

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Competitive Landscape:

BioReliance

Cobra Biologics

Oxford BioMedica

UniQure

FinVector

MolMed

MassBiologics

Richter-Helm

FUJIFILM Diosynth Biotechnologies

Lonza

Aldevron

Eurogentec

Cell and Gene Therapy Catapult

Biovian

Brammer Bio

VGXI

PlasmidFactory

Full Report is Ready, Complete Payment and Get this Premium Research [email protected] https://www.visionresearchreports.com/report/cart/24878

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Viral Vector amp; Plasmid DNA Manufacturing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Viral Vector amp; Plasmid DNA Manufacturing Market By Type
1.2.2.1. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share By Type in 2017
1.2.2.3. Lentivirus
1.2.2.4. Adenovirus
1.2.2.5. Plasmid DNA
1.2.2.6. Adeno-Associated Virus
1.2.2.7. Others
1.2.3. Viral Vector amp; Plasmid DNA Manufacturing Market By Application
1.2.3.1. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share By Application in 2017
1.2.3.3. Gene Therapy
1.2.3.4. Vaccinology
1.2.4. Viral Vector amp; Plasmid DNA Manufacturing Market By Disease
1.2.4.1. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.4.2. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share By Disease in 2017
1.2.4.3. Infectious Disease
1.2.4.4. Genetic Disorders
1.2.4.5. Cancer
1.2.4.6. Others
1.2.5. Viral Vector amp; Plasmid DNA Manufacturing Market By End Use
1.2.5.1. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share By End Use in 2017
1.2.5.3. Research Institutes
1.2.5.4. Biotech Companies
1.2.5.5. Others
1.2.6. Viral Vector amp; Plasmid DNA Manufacturing Market by Geography
1.2.6.1. Global Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Viral Vector amp; Plasmid DNA Manufacturing Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Viral Vector amp; Plasmid DNA Manufacturing Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Viral Vector amp; Plasmid DNA Manufacturing Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Viral Vector amp; Plasmid DNA Manufacturing Major Manufacturers in 2017

CHAPTER 4. Viral Vector amp; Plasmid DNA Manufacturing Market By Type

4.1. Global Viral Vector amp; Plasmid DNA Manufacturing Revenue By Type
4.2. Lentivirus
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Adenovirus
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Plasmid DNA
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Adeno-Associated Virus
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. Viral Vector amp; Plasmid DNA Manufacturing Market By Application

5.1. Global Viral Vector amp; Plasmid DNA Manufacturing Revenue By Application
5.2. Gene Therapy
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Vaccinology
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. Viral Vector amp; Plasmid DNA Manufacturing Market By Disease

6.1. Global Viral Vector amp; Plasmid DNA Manufacturing Revenue By Disease
6.2. Infectious Disease
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Genetic Disorders
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Cancer
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. Viral Vector amp; Plasmid DNA Manufacturing Market By End Use

7.1. Global Viral Vector amp; Plasmid DNA Manufacturing Revenue By End Use
7.2. Research Institutes
7.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.3. Biotech Companies
7.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 8. North America Viral Vector amp; Plasmid DNA Manufacturing Market By Country

8.1. North America Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. North America Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. U.S.
8.3.1. U.S. Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 9. Europe Viral Vector amp; Plasmid DNA Manufacturing Market By Country

9.1. Europe Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Europe Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 10. Asia-Pacific Viral Vector amp; Plasmid DNA Manufacturing Market By Country

10.1. Asia-Pacific Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Asia-Pacific Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 11. Latin America Viral Vector amp; Plasmid DNA Manufacturing Market By Country

11.1. Latin America Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Latin America Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 12. Middle East Viral Vector amp; Plasmid DNA Manufacturing Market By Country

12.1. Middle East Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Middle East Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 13. Africa Viral Vector amp; Plasmid DNA Manufacturing Market By Country

13.1. Africa Viral Vector amp; Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 ($Million)
13.2. Africa Viral Vector amp; Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 amp; 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. CobraBiologics
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Novasep
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Spark Therapeutics, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. FUJIFILM Diosynth Ltd
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Cell and Gene Therapy Catapult
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Kaneka Eurogentec, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Merck KGaA
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Lonza
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. UniQure N.V.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Others
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

Full Report is Ready, Complete Payment and Get this Premium Research [email protected] https://www.visionresearchreports.com/report/cart/24878

COMTEX_372025584/2630/2020-09-29T01:23:07

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Next Post

Pfizer Hosts 13th Africa and Middle East Oncology Summit To Discuss and Highlight Critical Topics and Advances in Oncology

Pfizer Inc. announced the successful completion of its 13th Africa and Middle East (AfME) Oncology Summit. The summit that brought together over 250 health care professionals from across the region focused on critical topics and insightful discussions at the forefront of breast cancer, genitourinary cancer (GU), and non-small-cell lung cancer […]